|
|
KIF1C |
kinesin family member 1C |
- COPI-dependent Golgi-to-ER retrograde traffic
- Kinesins
|
|
|
|
|
KIF5A |
kinesin family member 5A |
- MHC class II antigen presentation
- Insulin processing
- RHO GTPases activate KTN1
- COPI-dependent Golgi-to-ER retrograde traffic
- Kinesins
|
|
- Hereditary spastic paraplegia (SPG)
|
|
|
KLC1 |
kinesin light chain 1 |
- MHC class II antigen presentation
- RHO GTPases activate KTN1
- COPI-dependent Golgi-to-ER retrograde traffic
- Signaling by ALK fusions and activated point mutants
- Kinesins
|
|
|
|
|
KLC4 |
kinesin light chain 4 |
- MHC class II antigen presentation
- RHO GTPases activate KTN1
- COPI-dependent Golgi-to-ER retrograde traffic
- Kinesins
|
|
|
|
|
LATS2 |
large tumor suppressor kinase 2 |
|
|
|
|
|
LENG1 |
leukocyte receptor cluster member 1 |
- mRNA Splicing - Major Pathway
|
|
|
|
|
LMO2 |
LIM domain only 2 |
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
|
|
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
|
|
|
LRSAM1 |
leucine rich repeat and sterile alpha motif containing 1 |
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
LUC7L |
LUC7 like |
|
|
|
|
|
LZTS2 |
leucine zipper tumor suppressor 2 |
|
|
|
|
|
MAP2K5 |
mitogen-activated protein kinase kinase 5 |
|
|
|
|
|
MAPK14 |
mitogen-activated protein kinase 14 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- CD163 mediating an anti-inflammatory response
- Regulation of MITF-M-dependent genes involved in pigmentation
|
- Minocycline
- Dasatinib
- 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
- N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- Doramapimod
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- R-1487
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- SD-0006
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
- Fostamatinib
|
|
|
|
MBIP |
MAP3K12 binding inhibitory protein 1 |
- HATs acetylate histones
- Formation of WDR5-containing histone-modifying complexes
|
|
|
|
|
MBP |
myelin basic protein |
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
|
|
|
|
MSANTD3 |
Myb/SANT DNA binding domain containing 3 |
|
|
|
|
|
MSN |
moesin |
- Recycling pathway of L1
- Recycling pathway of L1
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- Sensory processing of sound by inner hair cells of the cochlea
- Sensory processing of sound by outer hair cells of the cochlea
- Signaling by ALK fusions and activated point mutants
|
|
|
|
|
MT-ND1 |
NADH dehydrogenase subunit 1 |
- Mitochondrial translation termination
- Respiratory electron transport
- Complex I biogenesis
- Mitochondrial protein degradation
|
- NADH
- Methoxyflurane
- Halothane
- Desflurane
- Sevoflurane
- N-Formylmethionine
- Phenethyl Isothiocyanate
|
- Leber optic atrophy; Leber hereditary optic atrophy (LHON)
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- Signaling by ALK
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
- Regulation of CDH1 mRNA translation by microRNAs
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
- Acetylsalicylic acid
- Dimethyl sulfoxide
- Doconexent
- Nadroparin
|
- Penile cancer
- Breast cancer
- Laryngeal cancer
- Oral cancer
- Multiple myeloma
- Kaposi's sarcoma
- Ovarian cancer
- Choriocarcinoma
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Burkitt lymphoma
- Small cell lung cancer
- Osteosarcoma
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
|
|
MYLIP |
myosin regulatory light chain interacting protein |
- VLDLR internalisation and degradation
- NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
MYOZ3 |
myozenin 3 |
|
|
|